

Christopher J Mcdougle

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5377323/publications.pdf>

Version: 2024-02-01

113
papers

8,035
citations

71004

43
h-index

56606

87
g-index

117
all docs

117
docs citations

117
times ranked

5181
citing authors

#	ARTICLE	IF	CITATIONS
1	A Virtually Delivered Adapted Cognitive-Behavioral Therapy Group for Adults With Williams Syndrome and Anxiety. <i>Cognitive and Behavioral Practice</i> , 2023, 30, 669-677.	0.9	6
2	Repetitive Thoughts and Repetitive Behaviors in Williams Syndrome. <i>Journal of Autism and Developmental Disorders</i> , 2022, 52, 852-862.	1.7	6
3	Buspirone for the Treatment of Generalized Anxiety Disorder in Down Syndrome: 3 Cases. <i>Journal of Developmental and Behavioral Pediatrics</i> , 2022, 43, 38-43.	0.6	4
4	Case Reports: Clozapine for the Treatment of Catatonia in Autism Spectrum Disorder. <i>Journal of Autism and Developmental Disorders</i> , 2022, 52, 2855-2858.	1.7	4
5	Parent Description of Anxiety in Angelman Syndrome. <i>Journal of Autism and Developmental Disorders</i> , 2022, 52, 3612-3625.	1.7	8
6	Brief Report: Suspected Cannabis-Induced Mania and Psychosis in Young Adult Males with Autism Spectrum Disorder. <i>Journal of Autism and Developmental Disorders</i> , 2022, 52, 4164-4171.	1.7	5
7	Neurodevelopmental Disorders Among Publicly or Privately Insured Children in the United States. <i>JAMA Psychiatry</i> , 2022, 79, 232.	6.0	31
8	Epigenetics of Autism Spectrum Disorder: Histone Deacetylases. <i>Biological Psychiatry</i> , 2022, 91, 922-933.	0.7	23
9	A randomized double-blind, placebo-controlled pilot trial of mirtazapine for anxiety in children and adolescents with autism spectrum disorder. <i>Neuropsychopharmacology</i> , 2022, 47, 1263-1270.	2.8	13
10	Association of Antipsychotic Drug Exposure in Pregnancy With Risk of Neurodevelopmental Disorders. <i>JAMA Internal Medicine</i> , 2022, 182, 522.	2.6	22
11	Stimulant intolerance in children with Angelman syndrome with hyperactivity: a case series. <i>Psychiatric Genetics</i> , 2022, 32, 80-86.	0.6	3
12	A rational pharmacologic approach toward a biologically meaningful subtype of autism spectrum disorder. <i>Jornal De Pediatria</i> , 2021, 97, 1-3.	0.9	0
13	Psychopharmacology of Williams syndrome: safety, tolerability, and effectiveness. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 293-306.	1.0	9
14	Gender Differences in Treatment-Seeking Youth with Autism Spectrum Disorder. <i>Journal of Child and Family Studies</i> , 2021, 30, 784-792.	0.7	4
15	Evaluation and Treatment of New-Onset Psychotic Symptoms in a Patient with Autism Spectrum Disorder and Multiple Autoimmune Disorders. <i>Harvard Review of Psychiatry</i> , 2021, 29, 378-387.	0.9	0
16	Recent Updates in Psychopharmacology for the Core and Associated Symptoms of Autism Spectrum Disorder. <i>Current Psychiatry Reports</i> , 2021, 23, 79.	2.1	8
17	Functional Neurological Symptom Disorder in Williams Syndrome: Case Series and Review of Relevant Literature. <i>Journal of the Academy of Consultation-Liaison Psychiatry</i> , 2021, , .	0.2	0
18	Sex-dependent neurobiological features of prenatal immune activation via TLR7. <i>Molecular Psychiatry</i> , 2020, 25, 2330-2341.	4.1	43

#	ARTICLE	IF	CITATIONS
19	Sleep as a translationally-relevant endpoint in studies of autism spectrum disorder (ASD). <i>Neuropsychopharmacology</i> , 2020, 45, 90-103.	2.8	32
20	Sleep and EEG biomarkers as avenues toward new treatment approaches in Angelman syndrome. <i>Neuropsychopharmacology</i> , 2020, 45, 238-239.	2.8	4
21	Bupirone for the Treatment of Generalized Anxiety Disorder in Williams Syndrome: A Case Series. <i>Journal of Autism and Developmental Disorders</i> , 2020, 50, 676-682.	1.7	6
22	Mobile device applications and treatment of autism spectrum disorder: a systematic review and meta-analysis of effectiveness. <i>Archives of Disease in Childhood</i> , 2020, 105, 458-462.	1.0	15
23	Treatment of Folate Metabolism Abnormalities in Autism Spectrum Disorder. <i>Seminars in Pediatric Neurology</i> , 2020, 35, 100835.	1.0	20
24	Paroxysmal oculogyric dystonia associated with a de novo 3q29 microdeletion. <i>Psychiatric Genetics</i> , 2020, 30, 119-123.	0.6	0
25	Rationale, design, and methods of the Autism Centers of Excellence (ACE) network Study of Oxytocin in Autism to improve Reciprocal Social Behaviors (SOARS-B). <i>Contemporary Clinical Trials</i> , 2020, 98, 106103.	0.8	14
26	Assessment of Speech and Fine Motor Coordination in Children With Autism Spectrum Disorder. <i>IEEE Access</i> , 2020, 8, 127535-127545.	2.6	24
27	Agitation in Patients With Autism Spectrum Disorder Admitted to Inpatient Pediatric Medical Units. <i>Pediatrics</i> , 2020, 145, S108-S116.	1.0	14
28	Characterization of sleep habits and medication outcomes for sleep disturbance in children and adults with Angelman syndrome. <i>American Journal of Medical Genetics, Part A</i> , 2020, 182, 1913-1922.	0.7	8
29	Immune Modulatory Treatments for Autism Spectrum Disorder. <i>Seminars in Pediatric Neurology</i> , 2020, 35, 100836.	1.0	6
30	New-Onset Abnormal Vocalizations in an Adult Woman With Down Syndrome. <i>Psychosomatics</i> , 2020, 61, 804-807.	2.5	1
31	Providing Inpatient Medical Care to Children With Autism Spectrum Disorder. <i>Hospital Pediatrics</i> , 2020, 10, 918-924.	0.6	16
32	Maternal and early postnatal immune activation produce sex-specific effects on autism-like behaviors and neuroimmune function in mice. <i>Scientific Reports</i> , 2019, 9, 16928.	1.6	98
33	Clinical Correlates of Parenting Stress in Children with Autism Spectrum Disorder and Serious Behavioral Problems. <i>Journal of Child and Family Studies</i> , 2019, 28, 2069-2077.	0.7	26
34	Challenges in the Medical Care of Patients With Autism Spectrum Disorder: The Role of the Consultation-Liaison Psychiatrist. <i>Psychosomatics</i> , 2019, 60, 435-443.	2.5	11
35	Beyond the brain: A multi-system inflammatory subtype of autism spectrum disorder. <i>Psychopharmacology</i> , 2019, 236, 3045-3061.	1.5	30
36	Women and Autism Spectrum Disorder: Diagnosis and Implications for Treatment of Adolescents and Adults. <i>Current Psychiatry Reports</i> , 2019, 21, 22.	2.1	79

#	ARTICLE	IF	CITATIONS
37	Buspirone for the treatment of anxiety-related symptoms in Angelman syndrome. <i>Psychiatric Genetics</i> , 2019, 29, 51-56.	0.6	11
38	An exploration of concomitant psychiatric disorders in children with autism spectrum disorder. <i>Comprehensive Psychiatry</i> , 2019, 88, 57-64.	1.5	72
39	Post-traumatic stress disorder following cardiac surgery: A case report of a nine-year-old female with Williams syndrome. <i>Journal of Intellectual and Developmental Disability</i> , 2019, 44, 244-247.	1.1	1
40	Comparison of Services for Autism Spectrum Disorder in Massachusetts with Those in Seoul. <i>Journal of Korean Medical Science</i> , 2019, 34, e288.	1.1	6
41	A randomized, placebo-controlled trial of extended-release guanfacine in children with autism spectrum disorder and ADHD symptoms: an analysis of secondary outcome measures. <i>Neuropsychopharmacology</i> , 2018, 43, 1772-1778.	2.8	52
42	Maternal and Early Postnatal Immune Activation Produce Dissociable Effects on Neurotransmission in mPFC Amygdala Circuits. <i>Journal of Neuroscience</i> , 2018, 38, 3358-3372.	1.7	65
43	Overweight and obese status in children with autism spectrum disorder and disruptive behavior. <i>Autism</i> , 2018, 22, 450-459.	2.4	53
44	Pharmacotherapy of Down syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1875-1889.	0.9	33
45	Another Step Toward Defining an Immune-Mediated Subtype of Autism Spectrum Disorder. <i>JAMA Network Open</i> , 2018, 1, e180280.	2.8	5
46	Brief Report: Major Depressive Disorder with Psychotic Features in Williams Syndrome: A Case Series. <i>Journal of Autism and Developmental Disorders</i> , 2018, 48, 947-952.	1.7	5
47	Perinatal Immune Activation Produces Persistent Sleep Alterations and Epileptiform Activity in Male Mice. <i>Neuropsychopharmacology</i> , 2018, 43, 482-491.	2.8	43
48	Multiple Antipsychotic Medication Use in Autism Spectrum Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2017, 27, 91-94.	0.7	23
49	d-Cycloserine enhances durability of social skills training in autism spectrum disorder. <i>Molecular Autism</i> , 2017, 8, 2.	2.6	35
50	Bone microarchitecture in adolescent boys with autism spectrum disorder. <i>Bone</i> , 2017, 97, 139-146.	1.4	19
51	Using a Patient-Centered Outcome Measure to Test Methylphenidate Versus Placebo in Children with Autism Spectrum Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2017, 27, 125-131.	0.7	17
52	Bone Accrual in Males with Autism Spectrum Disorder. <i>Journal of Pediatrics</i> , 2017, 181, 195-201.e6.	0.9	16
53	Rapid clinical deterioration in an individual with Down syndrome. <i>American Journal of Medical Genetics, Part A</i> , 2016, 170, 1899-1902.	0.7	23
54	Atypical Antipsychotic-Induced Weight Gain in Children and Adolescents. <i>JAMA Psychiatry</i> , 2016, 73, 899.	6.0	3

#	ARTICLE	IF	CITATIONS
55	Constance E. Lieber, Theodore R. Stanley, and the Enduring Impact of Philanthropy on Psychiatry Research. <i>Biological Psychiatry</i> , 2016, 80, 84-86.	0.7	2
56	No Apparent Cardiac Conduction Effects of Acute Treatment with Risperidone in Children with Autism Spectrum Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2016, 26, 900-908.	0.7	7
57	Attention Bias to Emotional Faces Varies by IQ and Anxiety in Williams Syndrome. <i>Journal of Autism and Developmental Disorders</i> , 2016, 46, 2174-2185.	1.7	19
58	A randomized, placebo-controlled trial of d-cycloserine for the enhancement of social skills training in autism spectrum disorders. <i>Molecular Autism</i> , 2016, 7, 2.	2.6	51
59	A randomized placebo-controlled pilot study of N-acetylcysteine in youth with autism spectrum disorder. <i>Molecular Autism</i> , 2016, 7, 26.	2.6	79
60	Sensitivity of the modified Children's Yale-Brown Obsessive Compulsive Scale to detect change: Results from two multi-site trials. <i>Autism</i> , 2016, 20, 145-152.	2.4	7
61	A Pilot Study of Autism-Specific Care Plans During Hospital Admission. <i>Pediatrics</i> , 2016, 137, S196-S204.	1.0	37
62	Psychopharmacological interventions in autism spectrum disorder. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 937-952.	0.9	93
63	Brief Report: Autism Spectrum Disorder and Substance Use Disorder: A Review and Case Study. <i>Journal of Autism and Developmental Disorders</i> , 2016, 46, 2514-2519.	1.7	29
64	Weight Gain and Metabolic Consequences of Risperidone in Young Children With Autism Spectrum Disorder. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2016, 55, 415-423.	0.3	61
65	Phenotypic differences in individuals with autism spectrum disorder born preterm and at term gestation. <i>Autism</i> , 2015, 19, 758-763.	2.4	22
66	A systematic review of molecular imaging (PET and SPECT) in autism spectrum disorder: Current state and future research opportunities. <i>Neuroscience and Biobehavioral Reviews</i> , 2015, 52, 56-73.	2.9	74
67	Evidence-Based Treatments for Autism Spectrum Disorder. <i>Current Treatment Options in Psychiatry</i> , 2015, 2, 38-56.	0.7	25
68	Multidisciplinary Assessment and Treatment of Self-Injurious Behavior in Autism Spectrum Disorder and Intellectual Disability: Integration of Psychological and Biological Theory and Approach. <i>Journal of Autism and Developmental Disorders</i> , 2015, 45, 1541-1568.	1.7	66
69	A Retrospective Naturalistic Study of Ziprasidone for Irritability in Youth with Autism Spectrum Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2015, 25, 397-401.	0.7	25
70	Tolerability, Safety, and Benefits of Risperidone in Children and Adolescents with Autism: 21-Month Follow-up After 8-Week Placebo-Controlled Trial. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2015, 25, 482-493.	0.7	61
71	Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder. <i>American Journal of Psychiatry</i> , 2015, 172, 1197-1206.	4.0	143
72	Toward an immune-mediated subtype of autism spectrum disorder. <i>Brain Research</i> , 2015, 1617, 72-92.	1.1	84

#	ARTICLE	IF	CITATIONS
73	N-Acetylcysteine for Neuropsychiatric Symptoms in a Woman With Williams Syndrome. <i>Journal of Child Neurology</i> , 2014, 29, NP135-NP138.	0.7	4
74	Atypical antipsychotics in the treatment of children and adolescents with pervasive developmental disorders. <i>Psychopharmacology</i> , 2014, 231, 1023-1036.	1.5	80
75	Impact of acamprosate on plasma amyloid- β^2 precursor protein in youth: A pilot analysis in fragile X syndrome-associated and idiopathic autism spectrum disorder suggests a pharmacodynamic protein marker. <i>Journal of Psychiatric Research</i> , 2014, 59, 220-228.	1.5	46
76	Neuroinflammation and Autism: Toward Mechanisms and Treatments. <i>Neuropsychopharmacology</i> , 2013, 38, 241-242.	2.8	11
77	The Effects of Aripiprazole on Electrocardiography in Children with Pervasive Developmental Disorders. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2012, 22, 277-283.	0.7	19
78	Risperidone-Related Improvement of Irritability in Children with Autism Is not Associated with Changes in Serum of Epidermal Growth Factor and Interleukin-13. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2011, 21, 555-564.	0.7	24
79	Medication and Parent Training in Children With Pervasive Developmental Disorders and Serious Behavior Problems: Results From a Randomized Clinical Trial. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2009, 48, 1143-1154.	0.3	279
80	Parent-Rated Anxiety Symptoms in Children with Pervasive Developmental Disorders: Frequency and Association with Core Autism Symptoms and Cognitive Functioning. <i>Journal of Abnormal Child Psychology</i> , 2008, 36, 117-128.	3.5	423
81	Serotonin and dopamine transporter binding in children with autism. <i>Developmental Medicine and Child Neurology</i> , 2008, 50, 565-565.	1.1	2
82	Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders. <i>Journal of Clinical Psychiatry</i> , 2008, 69 Suppl 4, 15-20.	1.1	35
83	Effects of Short- and Long-Term Risperidone Treatment on Prolactin Levels in Children with Autism. <i>Biological Psychiatry</i> , 2007, 61, 545-550.	0.7	142
84	Developmental Disabilities Modification of the Children's Global Assessment Scale. <i>Biological Psychiatry</i> , 2007, 61, 504-511.	0.7	64
85	Development of a parent training program for children with pervasive developmental disorders. <i>Behavioral Interventions</i> , 2007, 22, 201-221.	0.8	61
86	Open-Label Atomoxetine for Attention-Deficit/ Hyperactivity Disorder Symptoms Associated with High-Functioning Pervasive Developmental Disorders. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2006, 16, 599-610.	0.7	112
87	A Prospective Open Trial of Guanfacine in Children with Pervasive Developmental Disorders. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2006, 16, 589-598.	0.7	102
88	Risperidone for the Core Symptom Domains of Autism: Results From the Study by the Autism Network of the Research Units on Pediatric Psychopharmacology. <i>American Journal of Psychiatry</i> , 2005, 162, 1142-1148.	4.0	411
89	Acute and Long-Term Safety and Tolerability of Risperidone in Children with Autism. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2005, 15, 869-884.	0.7	147
90	Neurochemistry in the pathophysiology of autism. <i>Journal of Clinical Psychiatry</i> , 2005, 66 Suppl 10, 9-18.	1.1	48

#	ARTICLE	IF	CITATIONS
91	Guanfacine Treatment of Hyperactivity and Inattention in Pervasive Developmental Disorders: A Retrospective Analysis of 80 Cases. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2004, 14, 233-241.	0.7	109
92	A Naturalistic Retrospective Analysis of Psychostimulants in Pervasive Developmental Disorders. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2004, 14, 49-56.	0.7	90
93	Weight and Leptin Changes Among Risperidone-Treated Youths With Autism: 6-Month Prospective Data. <i>American Journal of Psychiatry</i> , 2004, 161, 1125-1127.	4.0	115
94	Increased Prevalence of Familial Autoimmunity in Proband With Pervasive Developmental Disorders. <i>Pediatrics</i> , 2003, 112, e420-e420.	1.0	222
95	Treatment of aggression in children and adolescents with autism and conduct disorder. <i>Journal of Clinical Psychiatry</i> , 2003, 64 Suppl 4, 16-25.	1.1	18
96	Risperidone in Children with Autism and Serious Behavioral Problems. <i>New England Journal of Medicine</i> , 2002, 347, 314-321.	13.9	1,379
97	Genetics of Childhood Disorders: XLIV. Autism, Part 3: Psychopharmacology of Autism. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2002, 41, 1380-1383.	0.3	26
98	Case Series: Use of Ziprasidone for Maladaptive Symptoms in Youths With Autism. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2002, 41, 921-927.	0.3	170
99	ECT in an Adolescent with Down Syndrome and Treatment-Refractory Major Depressive Disorder. <i>Journal of Developmental and Physical Disabilities</i> , 2002, 14, 291-295.	1.0	7
100	Tolerability Profile of Atypical Antipsychotics in Children and Adolescents. <i>Paediatric Drugs</i> , 2001, 3, 927-942.	1.3	47
101	Trichotillomania. <i>American Journal of Clinical Dermatology</i> , 2001, 2, 327-333.	3.3	80
102	The pathophysiology and treatment of autism. <i>Current Psychiatry Reports</i> , 2001, 3, 101-108.	2.1	8
103	A Naturalistic Open-Label Study of Mirtazapine in Autistic and Other Pervasive Developmental Disorders. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2001, 11, 267-277.	0.7	133
104	Repetitive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibitors. <i>Journal of Autism and Developmental Disorders</i> , 2000, 30, 427-435.	1.7	150
105	Brief report: two-year control of behavioral symptoms with risperidone in two profoundly retarded adults with autism. <i>Journal of Autism and Developmental Disorders</i> , 1999, 29, 87-91.	1.7	23
106	Olanzapine Treatment of Children, Adolescents, and Adults with Pervasive Developmental Disorders. <i>Journal of Clinical Psychopharmacology</i> , 1999, 19, 37-44.	0.7	199
107	Potential of Atypical Antipsychotics in the Treatment of Nonpsychotic Disorders. <i>CNS Drugs</i> , 1998, 9, 213-232.	2.7	23
108	A Double-blind, Placebo-Controlled Study of Risperidone in Adults With Autistic Disorder and Other Pervasive Developmental Disorders. <i>Archives of General Psychiatry</i> , 1998, 55, 633.	13.8	356

#	ARTICLE	IF	CITATIONS
109	Input from our Readers. <i>CNS Spectrums</i> , 1998, 3, 22-23.	0.7	27
110	Sertraline in Adults With Pervasive Developmental Disorders. <i>Journal of Clinical Psychopharmacology</i> , 1998, 18, 62-66.	0.7	121
111	Clomipramine in Adults with Pervasive Developmental Disorders: A Prospective Open-Label Investigation. <i>Journal of Child and Adolescent Psychopharmacology</i> , 1997, 7, 109-121.	0.7	94
112	A Double-blind, Placebo-Controlled Study of Fluvoxamine in Adults With Autistic Disorder. <i>Archives of General Psychiatry</i> , 1996, 53, 1001.	13.8	522
113	Clomipramine in Autism: Preliminary Evidence of Efficacy. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 1992, 31, 746-750.	0.3	144